{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T08:06:35Z","timestamp":1750925195330,"version":"3.38.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00120-024-02512-2","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T15:11:30Z","timestamp":1737558690000},"page":"220-228","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Stellenwert der PSMA-PET\/CT (\u201eprostate-specific membrane antigen positron emission tomography\/computed tomography\u201c) im Rahmen des Stagings","Role of prostate-specific membrane antigen positron emission tomography\/computed tomography (PSMA-PET\/CT) in staging"],"prefix":"10.1007","volume":"64","author":[{"given":"Claudia","family":"Kesch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Franiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Berliner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"2512_CR1","doi-asserted-by":"publisher","first-page":"tzae040","DOI":"10.1093\/bjro\/tzae040","volume":"6","author":"H Abdel-Aty","year":"2024","unstructured":"Abdel-Aty\u00a0H, Hujairi\u00a0N, Murray\u00a0I et\u00a0al (2024) The quantitative impact of prostate-specific membrane antigen (PSMA) PET\/CT staging in newly diagnosed metastatic prostate cancer and treatment-decision implications. BJR Open 6:tzae40. https:\/\/doi.org\/10.1093\/bjro\/tzae040","journal-title":"BJR Open"},{"key":"2512_CR2","unstructured":"Redaktion Deutsches \u00c4rzteblatt (2023) Zulassung f\u00fcr Radioligandentherapie \u2013 Prostatakrebs: Neue Option. https:\/\/www.aerzteblatt.de\/archiv\/229974\/Zulassung-fuer-Radioligandentherapie-Prostatakrebs-Neue-Option. Zugegriffen: 2. Nov. 2024"},{"key":"2512_CR3","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.2967\/jnumed.121.262120","volume":"62","author":"F Barbato","year":"2021","unstructured":"Barbato\u00a0F, Fendler\u00a0WP, Rauscher\u00a0I et\u00a0al (2021) PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease. J\u00a0Nucl Med 62:1747\u20131750. https:\/\/doi.org\/10.2967\/jnumed.121.262120","journal-title":"J Nucl Med"},{"key":"2512_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.eururo.2023.03.001","volume":"84","author":"KM Chow","year":"2023","unstructured":"Chow\u00a0KM, So\u00a0WZ, Lee\u00a0HJ et\u00a0al (2023) Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities for initial staging of intermediate- to high-risk prostate cancer: a\u00a0systematic review and meta-analysis. Eur Urol 84:36\u201348. https:\/\/doi.org\/10.1016\/j.eururo.2023.03.001","journal-title":"Eur Urol"},{"key":"2512_CR5","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1158\/1078-0432.CCR-19-1485","volume":"26","author":"K Current","year":"2020","unstructured":"Current\u00a0K, Meyer\u00a0C, Magyar\u00a0CE et\u00a0al (2020) Investigating PSMA-targeted radioligand therapy efficacy as a\u00a0function of cellular PSMA levels and Intratumoral PSMA heterogeneity. Clin Cancer Res 26:2946\u20132955. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1485","journal-title":"Clin Cancer Res"},{"key":"2512_CR6","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.2967\/jnumed.121.263611","volume":"63","author":"CS Denis","year":"2022","unstructured":"Denis\u00a0CS, Cousin\u00a0F, Laere\u00a0BD et\u00a0al (2022) Using 68Ga-PSMA-11 PET\/CT for therapy response assessment in patients with metastatic castration-resistant prostate cancer: application of EAU\/EANM recommendations in clinical practice. J\u00a0Nucl Med 63:1815\u20131821. https:\/\/doi.org\/10.2967\/jnumed.121.263611","journal-title":"J Nucl Med"},{"key":"2512_CR7","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1001\/jamaoncol.2020.4922","volume":"6","author":"RT Dess","year":"2020","unstructured":"Dess\u00a0RT, Suresh\u00a0K, Zelefsky\u00a0MJ et\u00a0al (2020) Development and validation of a\u00a0clinical prognostic stage group system for nonmetastatic prostate cancer using disease-specific mortality results from the international staging collaboration for cancer of the prostate. JAMA Oncol 6:1912\u20131920. https:\/\/doi.org\/10.1001\/jamaoncol.2020.4922","journal-title":"JAMA Oncol"},{"key":"2512_CR8","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.eururo.2023.06.022","volume":"84","author":"L Dja\u00efleb","year":"2023","unstructured":"Dja\u00efleb\u00a0L, Armstrong\u00a0WR, Thompson\u00a0D et\u00a0al (2023) Presurgical 68Ga-PSMA-11 positron emission tomography for biochemical recurrence risk assessment: a\u00a0follow-up analysis of a\u00a0multicenter prospective phase\u00a03 imaging trial. Eur Urol 84:588\u2013596. https:\/\/doi.org\/10.1016\/j.eururo.2023.06.022","journal-title":"Eur Urol"},{"key":"2512_CR9","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber\u00a0M, Herrmann\u00a0K, Calais\u00a0J et\u00a0al (2018) Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT. J\u00a0Nucl Med 59:469\u2013478. https:\/\/doi.org\/10.2967\/jnumed.117.198119","journal-title":"J Nucl Med"},{"key":"2512_CR10","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler\u00a0WP, Calais\u00a0J, Eiber\u00a0M et\u00a0al (2019) Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a\u00a0prospective single-arm clinical trial. JAMA Oncol 5:856\u2013863. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0096","journal-title":"JAMA Oncol"},{"key":"2512_CR11","doi-asserted-by":"publisher","first-page":"7448","DOI":"10.1158\/1078-0432.CCR-19-1050","volume":"25","author":"WP Fendler","year":"2019","unstructured":"Fendler\u00a0WP, Weber\u00a0M, Iravani\u00a0A et\u00a0al (2019) Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res 25:7448\u20137454. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1050","journal-title":"Clin Cancer Res"},{"key":"2512_CR12","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","volume":"22","author":"A Gafita","year":"2021","unstructured":"Gafita\u00a0A, Calais\u00a0J, Grogan\u00a0TR et\u00a0al (2021) Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol 22:1115\u20131125. https:\/\/doi.org\/10.1016\/S1470-2045(21)00274-6","journal-title":"Lancet Oncol"},{"key":"2512_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_350946","volume":"42","author":"A Gafita","year":"2022","unstructured":"Gafita\u00a0A, Marcus\u00a0C, Kostos\u00a0L et\u00a0al (2022) Predictors and real-world use of prostate-specific radioligand therapy: PSMA and beyond. Am Soc Clin Oncol Educ Book 42:1\u201317. https:\/\/doi.org\/10.1200\/EDBK_350946","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2512_CR14","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1007\/s00259-022-05882-x","volume":"49","author":"A Gafita","year":"2022","unstructured":"Gafita\u00a0A, Rauscher\u00a0I, Fendler\u00a0WP et\u00a0al (2022) Measuring response in metastatic castration-resistant prostate cancer using PSMA PET\/CT: comparison of RECIST\u00a01.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. Eur J Nucl Med Mol Imaging 49:4271\u20134281. https:\/\/doi.org\/10.1007\/s00259-022-05882-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2512_CR15","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.2967\/jnumed.121.263072","volume":"63","author":"A Gafita","year":"2022","unstructured":"Gafita\u00a0A, Rauscher\u00a0I, Weber\u00a0M et\u00a0al (2022) Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J\u00a0Nucl Med 63:1651\u20131658. https:\/\/doi.org\/10.2967\/jnumed.121.263072","journal-title":"J Nucl Med"},{"key":"2512_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102862","author":"K Herrmann","year":"2024","unstructured":"Herrmann\u00a0K, Gafita\u00a0A, de Bono\u00a0JS et\u00a0al (2024) Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase\u00a03 VISION trial. eClinicalMedicine. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102862","journal-title":"eClinicalMedicine"},{"key":"2512_CR17","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman\u00a0MS, Emmett\u00a0L, Sandhu\u00a0S et\u00a0al (2021) [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a\u00a0randomised, open-label, phase\u00a02\u00a0trial. Lancet 397:797\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(21)00237-3","journal-title":"Lancet"},{"key":"2512_CR18","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman\u00a0MS, Lawrentschuk\u00a0N, Francis\u00a0RJ et\u00a0al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a\u00a0prospective, randomised, multicentre study. Lancet 395:1208\u20131216. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7","journal-title":"Lancet"},{"key":"2512_CR19","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.2967\/jnumed.121.263441","volume":"63","author":"M Hotta","year":"2022","unstructured":"Hotta\u00a0M, Gafita\u00a0A, Czernin\u00a0J, Calais\u00a0J (2022) Outcome of patients with PSMA PET\/CT screen failure by VISION criteria and treated with 177Lu-PSMA therapy: a\u00a0multicenter retrospective analysis. J\u00a0Nucl Med 63:1484\u20131488. https:\/\/doi.org\/10.2967\/jnumed.121.263441","journal-title":"J Nucl Med"},{"key":"2512_CR20","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.2967\/jnumed.122.265242","volume":"64","author":"M Hotta","year":"2023","unstructured":"Hotta\u00a0M, Gafita\u00a0A, Murthy\u00a0V et\u00a0al (2023) PSMA PET tumor-to-salivary gland ratio to predict response to [177Lu]PSMA radioligand therapy: an international multicenter retrospective study. J\u00a0Nucl Med 64:1024\u20131029. https:\/\/doi.org\/10.2967\/jnumed.122.265242","journal-title":"J Nucl Med"},{"key":"2512_CR21","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S1470-2045(24)00326-7","volume":"25","author":"MJ Karpinski","year":"2024","unstructured":"Karpinski\u00a0MJ, H\u00fcsing\u00a0J, Claassen\u00a0K et\u00a0al (2024) Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a\u00a0multicentre retrospective study. Lancet Oncol 25:1188\u20131201. https:\/\/doi.org\/10.1016\/S1470-2045(24)00326-7","journal-title":"Lancet Oncol"},{"key":"2512_CR22","doi-asserted-by":"publisher","first-page":"e2440591","DOI":"10.1001\/jamanetworkopen.2024.40591","volume":"7","author":"N Kunst","year":"2024","unstructured":"Kunst\u00a0N, Long\u00a0JB, Westvold\u00a0S et\u00a0al (2024) Long-term outcomes of prostate-specific membrane antigen\u2013PET imaging of recurrent prostate cancer. JAMA Netw Open 7:e2440591. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.40591","journal-title":"JAMA Netw Open"},{"key":"2512_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.04.005","author":"WI Luining","year":"2024","unstructured":"Luining\u00a0WI, Boev\u00e9\u00a0LMS, Hagens\u00a0MJ et\u00a0al (2024) A comparison of globally applied prognostic risk groups and the prevalence of metastatic disease on prostate-specific membrane antigen positron emission Tomography in patients with newly diagnosed prostate cancer. Eur Urol Oncol. https:\/\/doi.org\/10.1016\/j.euo.2024.04.005","journal-title":"Eur Urol Oncol"},{"key":"2512_CR24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"M Perera","year":"2020","unstructured":"Perera\u00a0M, Papa\u00a0N, Roberts\u00a0M et\u00a0al (2020) Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a\u00a0systematic review and meta-analysis. Eur Urol 77:403\u2013417. https:\/\/doi.org\/10.1016\/j.eururo.2019.01.049","journal-title":"Eur Urol"},{"key":"2512_CR25","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor\u00a0O, de Bono\u00a0J, Chi\u00a0KN et\u00a0al (2021) Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N\u00a0Engl J Med 385:1091\u20131103. https:\/\/doi.org\/10.1056\/NEJMoa2107322","journal-title":"N Engl J Med"},{"key":"2512_CR26","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher\u00a0HI, Morris\u00a0MJ, Stadler\u00a0WM et\u00a0al (2016) Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group\u00a03. J\u00a0Clin Oncol 34:1402\u20131418. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702","journal-title":"J Clin Oncol"},{"key":"2512_CR27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert\u00a0R, Emmett\u00a0L, Rowe\u00a0SP et\u00a0al (2023) Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol 83:405\u2013412. https:\/\/doi.org\/10.1016\/j.eururo.2023.02.002","journal-title":"Eur Urol"},{"key":"2512_CR28","doi-asserted-by":"publisher","first-page":"7812","DOI":"10.7150\/thno.47251","volume":"10","author":"R Seifert","year":"2020","unstructured":"Seifert\u00a0R, Seitzer\u00a0K, Herrmann\u00a0K et\u00a0al (2020) Analysis of PSMA expression and outcome in patients with advanced prostate cancer receiving 177Lu-PSMA-617 radioligand therapy. Theranostics 10:7812\u20137820. https:\/\/doi.org\/10.7150\/thno.47251","journal-title":"Theranostics"},{"key":"2512_CR29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.euf.2019.06.004","volume":"6","author":"T Van den Broeck","year":"2020","unstructured":"Van den Broeck\u00a0T, van den Bergh\u00a0RCN, Briers\u00a0E et\u00a0al (2020) Biochemical recurrence in prostate cancer: the European association of urology prostate cancer guidelines panel recommendations. Eur Urol Focus 6:231\u2013234. https:\/\/doi.org\/10.1016\/j.euf.2019.06.004","journal-title":"Eur Urol Focus"},{"key":"2512_CR30","unstructured":"TNM Klassifikation maligner Tumoren. https:\/\/www.wiley-vch.de\/de\/fachgebiete\/medizin-und-gesundheit\/tnm-klassifikation-maligner-tumoren-978-3-527-34280-8. Zugegriffen: 1. Nov. 2024"},{"key":"2512_CR31","unstructured":"Schaeffer E, Srinivas S, Armstrong AJ et\u00a0al NCCN clinical practice guidelines in oncology: prostate cancer, version 4.2024. https:\/\/www.nccn.org\/docs\/default-source\/business-policy\/nccn-referencing-guidance.pdf. Zugegriffen: 2. Nov. 2024"},{"key":"2512_CR32","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2024) S3-Leitlinie Prostatakarzinom, Langversion 7.0. https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/prostatakarzinom\/;. Zugegriffen: 5. Nov. 2024 (AWMF-Registernummer: 043-022OL)"},{"key":"2512_CR33","unstructured":"https:\/\/humanhealth.iaea.org\/HHW\/DBStatistics\/IMAGINEMaps4.html;. Zugegriffen: 7. Dez. 2024"},{"key":"2512_CR34","unstructured":"https:\/\/www.asv-servicestelle.de\/asv-verzeichnis;. Zugegriffen: 7. Dez. 2024"},{"key":"2512_CR35","unstructured":"https:\/\/dserver.bundestag.de\/btd\/20\/138\/2013849.pdf;. Zugegriffen: 7. Dez. 2024"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02512-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-024-02512-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02512-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T17:51:46Z","timestamp":1741629106000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-024-02512-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2512"],"URL":"https:\/\/doi.org\/10.1007\/s00120-024-02512-2","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"type":"print","value":"2731-7064"},{"type":"electronic","value":"2731-7072"}],"subject":[],"published":{"date-parts":[[2025,1,22]]},"assertion":[{"value":"18 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Kesch: Forschungsf\u00f6rderung: Novartis, Amgen, Mariana Oncology; Honoraria: Pfizer, Novartis; Reiseunterst\u00fctzung: Bayer. T.\u00a0Franiel: Forschungsf\u00f6rderung: Zentrales Innovationsprogramm Mittelstand des Bundesministeriums f\u00fcr Wirtschaft und Energie (ZF4816001BA9), Siemens Healhineers, Beratert\u00e4tigkeit: Bayer AG, Onkowissen, Honorare f\u00fcr Vortr\u00e4ge und Buchbeitr\u00e4ge: Bayer AG, Saegeling Medizintechnik, Medac Gmbh, Georg Thieme Verlag, Sonstiges: Mitglied der S3 Leitliniengruppe f\u00fcr das Prostatakarzinom. C.\u00a0Berliner: Beratert\u00e4tigkeit: Advanced Accelerator Applications, (Novartis Tochterunternehmen); GE Healthcare; Janssen Pharma. W.P.\u00a0Fendler: Beratert\u00e4tigkeit: Janssen, Perceptive, Bayer, Novartis, GE Healthcare, Lilly; Forschungsf\u00f6rderung: SOFIE Bioscience, Bayer; Honoraria: Janssen, Perceptive, Bayer, Novartis, Telix, GE Healthcare, Eczac\u0131ba\u015f\u0131 Monrol, Abx, Amgen, Urotrials. K.\u00a0Herrmann: Beratert\u00e4tigkeit: Advanced Accelerator Applications (Novartis Tochterunternehmen), Amgen, AstraZeneca, Bain Capital, Bayer, Boston Scientific, convergent, CuriumDebiopharm, EcoR1, Fusion, Ge Healthcare, Immedica, Isotopen Technologien M\u00fcnchen, Janssen, Merck, MSD, Molecular Partners, NVision, POINT Biopharma, Pentixapharm, Pfizer, Radiopharm Theranostics, Rhine Pharma, Siemens Healthineers, Sofie Biosciences, Telix, Theragnostics, ymabs; Forschungsf\u00f6rderung: Advanced Accelerator Applications (Novartis Tochterunternehmen), Boston Scientific, Janssen; Eigentumsanteile: AdvanCell, Aktis Oncology, Convergent, NVision and Sofie Biosciences. B.\u00a0Hadaschik: Beratert\u00e4tigkeit: Lightpoint medical, Janssen, Bayer, Abx, Amgen, Astellas, Merck, Amgen, MSD, Novartis, BMS, Onkowissen, POINT Biopharma, Pfizer, Ipsen, Accord Healthcare, Telix; Reiseunterst\u00fctzung: Amgen, AstraZeneca, Bristol-Myers Squibb, Janssen, Bayer, and Ipsen; Forschungsf\u00f6rderung: Johnson&Johnson, Novartis, BMS.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}